Meiji Seika Pharma
As of the edition of 20 October 2026, Meiji Seika Pharma runs 16 drugs, 11 of them marketed; it is on route A at 0 targets and on route B at 6 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 11 |
| Active | 1 |
| Went quiet | 4 |
| Total | 16 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Daunorubicin | none listed | 2 |
| Fluvoxamine | none listed | 3 |
| Asenapine | Ended 2026 (patent) | 3 |
| Belumosudil | Ends 2034 (patent) | 4 |
| Ampicillin | none listed | 0 |
| Penicillin g | none listed | 0 |
| Safinamide | Ends 2028 (patent) | 1 |
| Stiripentol | Ends 2029 (exclusivity) | 0 |
| Talaporfin | none listed | 0 |
| Streptomycin | none listed | 0 |
| Cefditoren pivoxil | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 6 targets.
All 6 rows on route A or B
In the product6 company-target rows on route A or B; 3 are not shown here, and no score is.
See all 6 targets where Meiji Seika Pharma needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Infections: 5 trials led
- Skin and connective tissue: 2 trials led
- Lungs and airways: 1 trials led